Our results with copanlisib in PIK3CA mutated recurrent endometrial cancer patients are consistent with the recent literature and suggest limited activity of single agent PIK3CA inhibitors in the treatment of chemotherapy-resistant, recurrent human solid tumors (Janku et al., 2018). The gene discussed is PIK3CA; the disease is endometrial cancer.